This is a marketing communication. Please refer to the prospectus/information document of the fund and to the KIID/KID (as applicable) before making any final investment decisions.

For information purposes only, this presentation should not be used as a basis for investment decision.

Asset Management March 31, 2024



Sustainable Thematic

CS (Lux) Digital Health Equity Fund UBH CHF

Fund information

Equity

1'483'639'289 Fund total net assets in USD						
Share class TNA, CHF	Share class NAV, CHF	Management fee p.a. ¹				
56'893'994	122.60	0.90%				
MTD (net) return	OTD (net) return	YTD (net) return				
-1.34%	0.59%	0.59%				

Investment Policy

Health care cost to society has risen to levels which are no longer sustainable. This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology. It offers diversified exposure to the digital health universe, which is one of the fastest growing segments in the health care industry. The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in "pure-play" digital health companies, which are typically small to mid-sized. The investment objective is long-term capital appreciation from actively managed exposure to this secular growth theme.

Fund details

Investment Manager	Thomas Amrein, Fang Liu
Fund launch date	14.12.2017
Share class launch date	14.12.2017
Share class	UBH
Share class currency	CHF
Distribution policy	Accumulating
Fund domicile	Luxembourg
ISIN	LU1683288697
Benchmark	No benchmark



Investing involves risk including the risk of loss of capital. Past performance does not predict future returns. Neither simulated nor historical performance is a reliable indicator for current or future performance.



since 01.01.2018, in %							
	2018	2019	2020	2021	2022	2023	2024
Portfolio net	-0.50	29.52	83.75	-20.39	-38.49	4.12	0.59

¹ If the currency of a financial product and/or its costs is different from your reference currency, the return and cost may increase or decrease as a result of currency fluctuations.

The individuals mentioned above only conduct regulated activities in the jurisdiction(s) where they are properly licensed, where relevant.

ESG stands for environmental (E), social (S), and governance (G).

Please find the definition of all the acronyms/terms used in this document in the Glossary. Additional important information can be found at the end of the document.

Performance overview

since 01.01.2018, in %

Risk overview - ex post

since 01.01.2018, in %

	Rolling Returns			Annualized Returns					Annualize	d risk, in %	
	1 months 3	months	1 year	3 years	5 years	ITD		1 year	3 years	5 years	ITD
Portfolio net	-1.34	0.59	0.06	-18.46	0.59	3.16	Portfolio volatility	34.29	29.85	28.61	28.12

Potential Risks

The Fund's risk and reward profile does not reflect the risk inherent in future circumstances that differ from what the Fund has experienced in the recent past. This includes the following events which are rare but can have a large impact.

- Credit risk: Issuers of assets held by the Fund may not pay income or repay capital when due. The Fund's investments have low credit risk. Liquidity risk: Assets cannot necessarily be sold at limited cost in an adequately short timeframe. The Fund's investments may be .
- prone to limited liquidity. The Fund will endeavor to mitigate this risk by various measures. Counterparty risk: Bankruptcy or insolvency of the Fund's derivative counterparties may lead to payment or delivery default.
- Operational risk: Deficient processes, technical failures or catastrophic events may cause losses
- Political and Legal risks: Investments are exposed to changes of rules and standards applied by a specific country. This includes restrictions on currency convertibility, the imposing of taxes or controls on transactions, the limitations of property rights or other legal risks
- Sustainability risks: Sustainability risks are environmental, social or governance events or conditions that can have a material

negative effect on the return, depending on the relevant sector, industry and company exposure. The product's investment objectives, risks, charges and expenses, as well as more complete information about the product, are provided in the prospectus (or relevant offering document), which should be read carefully before investing.

Investors may lose part or all of their invested amount.

The full offering documentation including complete information on risks may be obtained free of charge from a Credit Suisse client advisor, representative, or, where applicable, via Fundsearch (credit-suisse.com/fundsearch).

The investment promoted in this marketing material concerns the acquisition of units or shares in a fund and not of any underlying assets. The underlying assets are owned by the fund only.

Asset breakdown by subtheme

In % of total economic exposure		
	in %	Portfolio
Treatments	46.89	
Efficiency	27.81	
R&D	25.28	
Cash/Cash Equivalents	0.02	

Asset breakdown by risk country

In % of total acor

	in %	Portfolio
United States	74.77	
Japan	5.55	
China	4.60	
Netherlands	4.46	
Denmark	3.79	
Switzerland	3.32	
Israel	1.67	
Canada	1.40	
Germany	1.37	
Others	-0.92	

Asset breakdown by risk currency (before hedging)

In % of total economic exposure


USD 73.46 EUR 5.99 JPY 5.45 CNH 4.51 DKK 3.72 CHF 3.16 ILS 1.64 CAD 1.37 GBP 0.71 HKD 0.00		in %	Portfolio
JPY 5.45 CNH 4.51 DKK 3.72 CHF 3.16 ILS 1.64 CAD 1.37 GBP 0.71	USD	73.46	
CNH 4.51 DKK 3.72 CHF 3.16 ILS 1.64 CAD 1.37 GBP 0.71	EUR	5.99	
DKK 3.72 CHF 3.16 ILS 1.64 CAD 1.37 GBP 0.71	JPY	5.45	
CHF 3.16 ILS 1.64 CAD 1.37 GBP 0.71	CNH	4.51	
ILS 1.64 CAD 1.37 GBP 0.71	DKK	3.72	
CAD 1.37 GBP 0.71	CHF	3.16	
GBP 0.71	ILS	1.64	
	CAD	1.37	
HKD 0.00	GBP	0.71	
0.00	HKD	0.00	

Key figures

Portfolio Number of securities 54

Fund Statistics - ex post			
	1 year	3 years	5 years
	Portfolio	Portfolio	Portfolio
Maximum drawdown, in %	-33.68	-62.39	-64.05

² The risk indicator assumes you keep the Product for 7 years. The actual risk can vary significantly if you redeem at an early stage and you may get back less. The Summary Risk Indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets. Be aware of currency risk if your reference currency differs from the currency of the Product. You may receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. Investors shall note that the Product may be exposed to further risks such as operational, counterparty, political, sustainability and legal risks that are not included in the Summary Risk Indicator. This Product does not include any protection from future market performance so you could lose some or all of your investment.



Larger values (up to 7) indicate higher risk while lower values (up to 1) indicate lower risk.

Past performance does not predict future returns. Neither simulated nor historical performance is a reliable indicator for current or future performance.

-

Largest contributors and detractors

MTD as of 31.03.2024

			Portfolio
Contributors ³	Total return	Weight	Total effect
SHOCKWAVE MEDICAL INC	24.41%	3.66%	0.82%
INSPIRE MEDICAL SYSTEMS INC	19.95%	3.80%	0.69%
EXACT SCIENCES CORP	20.04%	3.26%	0.61%
DEXCOM INC	20.54%	2.99%	0.52%
KRYSTAL BIOTECH INC	11.69%	3.42%	0.38%

Detractors ³	Total return	Weight	Portfolio Total effect
Detractors	Total return	weight	Total effect
ZAI LAB LTD	-24.26%	2.94%	-0.81%
10X GENOMICS INC CLASS A	-19.50%	3.40%	-0.74%
CRISPR THERAPEUTICS AG	-19.07%	2.71%	-0.57%
TWIST BIOSCIENCE CORP	-12.67%	3.22%	-0.44%
RECURSION PHARMACEUTICALS	-25.93%	1.26%	-0.39%

Largest contributors and detractors

YTD as of 31.03.2024

			Portfolio				Portfolio
Contributors ³	Total return	Weight	Total effect	Detractors ³	Total return	Weight	Total effect
SHOCKWAVE MEDICAL INC	70.30%	3.82%	2.08%	ZAI LAB LTD	-40.15%	3.01%	-1.52%
ZEALAND PHARMA	79.02%	3.14%	1.80%	10X GENOMICS INC CLASS A	-32.87%	3.72%	-1.41%
NATERA INC	45.73%	3.50%	1.37%	SCHRODINGER INC	-24.42%	3.43%	-0.93%
KRYSTAL BIOTECH INC	43.67%	3.13%	1.25%	JD HEALTH INTERNATIONAL INC	-29.32%	1.92%	-0.71%
IOVANCE BIOTHERAPEUTICS INC	82.52%	1.44%	0.98%	INARI MEDICAL INC	-26.17%	2.32%	-0.70%

Performance commentary

The strategy underperformed the benchmark in Q1 2024. The performance of the benchmark being concentrated in a handful of tech-related names created additional headwind for our thematic approach as we do not own these names. The Treatment sub-theme is the best performer this quarter while R&D and Efficiency lagged. We have seen a rebound of the medtech sector, which was heavily beaten down by GLP-1 concerns in the second half of 2023. The largest performance contributors in the first quarter were Shockwave, Zealand Pharma, and Natera. Shockwave reported solid Q4 results and further climbed in March as news reports indicated acquisition interest from Johnson & Johnson. Zealand Pharma published positive Phase IIb data for its differentiated compound survodutide in treating liver disease (MASH) related to obesity. Natera almost doubled from its 2023 low after it posted strong Q4 results, won the patent litigation case against CareDx, and received further Medicare coverage for its Signatera Minimal Residual Disease tests for two new indications. The largest performance detractors were Zai Lab, 10x Genomics, and Schrodinger. Zai Lab pulled back heavily due to extremely negative sentiment around Chinese stocks caused by geopolitical concerns. 10x Genomics successfully launched its new platform Xenium, but guidance for the year was weaker than expected due to budget constraints at the major academic labs, especially in China. Schrodinger disappointed after it guided lukewarm revenue growth for its software business, retreating from Al momentum.

Market comments

In the first quarter of 2024, global equity markets advanced strongly, with S&P reaching an all-time high buoyed by more economic indicators pointing to a soft landing in the U.S. Major indices were pushed up by a tech-driven rally amid artificial intelligence (AI) exuberance. Rate cuts are still on the Fed's agenda this year but the timing and trajectory have become less certain as inflation and employment metrics appeared to suggest a need to keep the rates "higher for longer," which ignited significant market volatility. At sector level, S&P 500 healthcare index underperformed S&P 500 slightly and the divergence of performance between large-cap and small-and-mid-cap healthcare stocks persisted. The rush for "quality names" combined with possibly "later and less" rate cuts disproportionately affect the funding costs of unprofitable companies, which markes the market reluctant to buy into the longer-term success of these companies at this moment.

Comments on transactions

In Q1, we fully exited Axonics and Omnicell. Axonics was acquired by Boston Scientific in January at \$71 cash per share (CNBC, January 8, 2024). The investment case for Omnicell failed to hold after the management team disappointed multiple times on execution and announced a bewildering business operation review. We initiated a new position in Privia Health, deeming it one of the only value-based care names with a sustainable and profitable business model. We continued to trim positions exceeding 4%, such as Zealand Pharma and Redcare Pharmacy, and add to those that were heavily beaten down on negative sentiment, such as Transmedics.

This commentary is intended only to describe past performance of the investment strategy. The strategy invests in individual securities which are owned in the strategy as part of a carefully constructed and diversified portfolio. The information presented in this commentary may be based on the assessment of CS' portfolio managers. Market developments described in this document are subject to a number of risks and uncertainties and are neither reliable indicators nor a guarantee of future results/performance. The information in this commentary may change after the date of issuance of this document without notice and should not be construed as a recommendation to buy or sell individual securities named herein.

Key facts

Key identifiers

investment

Instrument Name	Credit Suisse (Lux) Digital Health Equity Fund UBH	Fund management company	Credit Suisse Fund Management S.A.
	CHF	UCITS	Yes
ISIN	LU1683288697	SFDR Classification	Article 8
Bloomberg ticker	CSGDUBH LX	Accounting year end	31. May
Valor no.	38312206	Securities lending	Yes
Benchmark	No benchmark	Ongoing charges ⁴	1.24%
		Subscription notice period	daily
		Subscription settlement period	T + 2
		Redemption notice period	daily
		Redemption settlement period	T + 2
		Cut-off time	15:00 CET
		Swinging single pricing (SSP*)	partial swing NAV

³ The individual entities and/or instruments mentioned on this page are meant for illustration purposes only and are not intended as a solicitation or an offer to buy or sell any interest or any

4 If the currency of a financial product and/or its costs is different from your reference currency, the return and cost may increase or decrease as a result of currency fluctuations.

ESG Approach

This fund promotes environmental, social and governance (ESG) characteristics (within the meaning of Art. 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector). It applies the CSAM Sustainable Investing Policy (www.credit-suisse.com/esg), including norms-based, values-based and business conduct exclusions, to combine ESG factors with traditional financial analysis to make an ESG adjusted risk-return assessment, which serves as the basis for the portfolio construction. For further information about the ESG investment criteria and the sustainability-related aspects of the fund please consider the legal and regulatory documents of the fund (such as, e.g., the prospectus) and visit www.credit-suisse.com/esg. In addition to sustainability-related aspects, the decision to invest in the fund should take into account all objectives and characteristics of the fund as described in its prospectus, or in the information which is to be disclosed to investors in accordance with applicable regulations.

Certain data points are provided for mere transparency purposes and are not linked to a specific ESG investment process, nor to CSAM ESG methodology. For details about the fund's ESG decision-making process, please refer to the fund's prospectus.

ESG Characteristics

ESG Benchmark	Exclusion Criteria	ESG Integration	Active Ownership ⁵	Sustainable Investment Objective
\mathbf{Z}	\mathbf{V}	\checkmark	\checkmark	

ESG Overview

According to MSCI methodology. Fund performance against benchmark: MSCI World ESG Leaders (NR).

	Portfolio	Benchmark
ESG Rating	BBB	AA
ESG Quality score	5.51	7.77
Environmental score	6.37	6.62
Social score	4.52	5.47
Governance score	5.99	5.94
Coverage for Rating/Scoring	95.92%	99.96%
Weighted Average Carbon Intensity (Tons of CO2e/\$M sales)	17.54	60.47
Coverage for Carbon Intensity	94.59%	99.79%

Note: The total carbon intensity figure shown in this section may be higher than the total in the breakdown graph. This is because the figure is normalized, and actual weights are inflated because of limited data coverage. For further information on the MSCI methodology for the above listed ESG data points, please refer to the glossary.

Top 10 positions - ESG Characteristics

In terms of the fund's total economic exposure. Certain data points disclosed in this table are provided for mere transparency purposes and are not linked to a specific ESG investment process, nor to CSAM ESG methodology. For details about the fund's ESG decision-making process, please refer to the fund's prospectus. Source: MSCI

Instrument Name ⁶	Weight in portfolio	GICS sector	MSCI ESG Rating	Controversy flag	Carbon intensity (tCO2e / \$M sales)
REDCARE PHARMACY NV	4.38%	Consumer Staples	AAA	Green	1.80
TRANSMEDICS GROUP INC	3.98%	Health Care	BBB	Green	15.60
VEEVA SYSTEMS INC CLASS A	3.90%	Health Care	А	Green	0.20
SHOCKWAVE MEDICAL INC	3.83%	Health Care	А	Green	1.40
INSPIRE MEDICAL SYSTEMS INC	3.76%	Health Care	BBB	Green	15.60
NATERA INC	3.75%	Health Care	В	Green	12.60
ZEALAND PHARMA	3.72%	Health Care	BBB	Green	49.70
EXACT SCIENCES CORP	3.72%	Health Care	А	Yellow	12.50
KRYSTAL BIOTECH INC	3.47%	Health Care	BBB	Green	33.43
SCHRODINGER INC	3.45%	Health Care	В	Green	6.20

Note: All ESG data points in the table refer to an underlying issuer as applicable (e.g., an equity issuer in case of a convertible bond). For further information on the methodology for the above listed ESG data points, please refer to the glossary.

Asset breakdown by ESG rating

In % of total economic exposure. Fund performance against benchmark: MSCI World ESG Leaders (NR). Source: MSCI ESG rating

	Portfolio	Benchmark	Portfolio Benchmark
AAA	4.38	26.06	
AA	7.86	44.22	
A	25.56	22.31	
BBB	42.31	6.89	
BB	7.21	0.48	
В	8.60	-	
CCC	-	-	
Not ratable	0.02	0.00	
No data coverage	4.06	0.03	-

Asset breakdown by ESG controversy flag

In % of fund total economic exposure to investee companies. Fund performance against benchmark: MSCI World ESG Leaders (NR). Source: MSCI

	Portfolio	Benchmark	Portfolio Benchmark
Green	90.89	40.69	
Yellow	6.14	42.40	
Orange	0.54	16.87	
Red	-	-	
No data coverage	2.42	0.03	•

Note: Exposure to investee companies represents 99.98% of portfolio weight for this share class. MSCI only provides data on ESG controversies for corporate issuers. Any remaining instruments (e.g., government bonds) are excluded from this breakdown. For further information on MSCI's ESG controversy flag methodology, please refer to the glossary.

Note: For further information on MSCI's ESG rating methodology and the difference between categories "not ratable" and "no data coverage", please refer to the glossary.

⁵ Active Ownership is part of the fund's strategy to act in the best interests of its investors and to preserve and optimize the long-term value of their investments. To promote best practices and to ensure that the investee companies are sustainable and successful in the long term, Active Ownership is designed to influence the investee companies on two levels: first, through proxy voting, and second, through engagement. In the case of investments in other funds (Target Funds), the fund has no or only limited ability to exercise Active Ownership on the Target Fund, resp. on the Target Funds.

⁶ The individual entities and/or instruments mentioned on this page are meant for illustration purposes only and are not intended as a solicitation or an offer to buy or sell any interest or any investment.

Carbon emission intensity contribution by GICS sector

Tons of CO2 equivalent emission intensity (GHG scopes 1 & 2) per \$m sales, by GICS sector split. Fund performance against benchmark: MSCI World ESG Leaders (NR). Source: MSCI

	Portfolio	Benchmark	Benchmark
Health Care	17.80	1.81	
Consumer Staples	0.08	2.94	
Cash	0.00	0.00	
FX	0.00	0.00	
Others	0.00	55.59	
Total	17.89	60.34	

Note: Security weighted data coverage is 94.59% for the portfolio. The total shown in this section may be lower than the one in the 'ESG Overview' section. This is because the figures in this breakdown are not normalized and use the actual weights. For further information on the Carbon emission intensity, please refer to the glossary.

Glossary

Accumulating	Indicates a regular reinvestment of the dividends received in the portfolio itself			
Annualized Risk	Annualized risk is a statistic, which is used to measure the risk of a fund by describing the range of returns, which were achieved in the observation period are most likely to be achieved. Greater volatility implies greater risk.			
Carbon emission intensity	The weighted average emissions intensity, which is provided by MSCI ESG, divides the Scopes 1 & 2 emissions in tons of CO2-equivalent by million \$ sales. Intensities are broken down by GICS sector and are security weighted.			
ESG benchmark	A ticked 'ESG benchmark' box reflects that the ESG section in this document compares the ESG performance of the portfolio with an ESG index. In case the box not ticked, this means that the ESG section in this document compares the ESG performance of the portfolio with a non-ESG index or that no comparison is performed due to a lack of a recognized benchmark. The investor shall read the legal documentation of the Fund to understand how the benchmark is used. In a case, a ticked 'ESG benchmark' box does not mean that the ESG benchmark is used to attain the ESG strategy of the fund.			
ESG Controversy Flag	ESG Controversy Flag is designed to provide timely and consistent assessments of ESG controversies involving publicly traded companies and fixed income issuers. A controversy case is typically a one-off event such as an environmental oil spill, an accident, or allegations such as safety issues in a production facility. Controversy flags can be red, orange, yellow or green. Red indicates that a company is involved in one or more very severe controversies. Orange indicates that a company has been involved in one or more recent severe structural controversies that are ongoing. Yellow indicates that the company is involved in severe-to-moderate level controversies. Green indicates that the company is not involved in any major controversies. For further information on the methodology, please refer to www.msci.com/our-solutions/esg-investing/.			
ESG Quality score	The ESG Quality score, based on MSCI ESG scores of underlyings, is measured on a scale from 0 (very poor) to 10 (very good). It does not correspond directly to the underlying Environment, Social and Governance Pillar scores. The Pillar scores are derived on an absolute basis, while the portfolio ESG Quality score is adjusted by MSCI to reflect the industry-specific level of ESG risk exposure. As Pillar scores are absolute, and the portfolio ESG Quality score is relative, the first cannot be averaged to derive the latter. The coverage rate is security weighted.			
Issuer ESG Rating	Company and Government ESG Ratings, which are provided by MSCI ESG, are measured on a scale from AAA (highest rating) to CCC (lowest rating). Company ESG Ratings are based on the issuer's exposure to industry specific ESG risks and its ability to mitigate those risks relative to peers. Company ESG Ratings are calculated on an industry relative basis while the underlying individual E, S and G Ratings are absolute. Hence, the ESG Rating cannot be seen as an average of the individual E, S and G Ratings. Government ESG Ratings identify a country's exposure to and management of ESG risk factors and explain how these factors might impact the long-term sustainability of its economy. They are derived from 0-10 scores on underlying factors in the E, S and G pillars. For further information on the MSCI methodology, please refer to www.msci.com/our-solutions/esg-investing/.			
Ex post	Refers to metrics based on historical data			
GICS	Global Industry Classification Standard			
Greenhouse gas (GHG) emissions	Scope 1 emissions are generated by a company directly from owned or controlled sources such as the burning of fuels (stationary or mobile), industrial processes, etc. Scope 2 emissions are indirect emissions, primarily those associated with the electricity consumed by a company. Scope 3 emissions are all other indirect emissions associated with a company's operations, such as business travel, waste generated, and products both upstream (in the supply chain) and downstream (use of the products and end of life). Scope 3 emissions typically account for the largest proportion of a company's emissions.			
ITD	Inception-to-date			
Maximum drawdown	Represents the worst possible result (in percentage terms) that occurred during the period being analyzed.			
MTD	Month-to-date			
LuxFLAG ESG	For more information about the methodology and label validity, please visit luxflag.org. Validity: 01 January 2024 - 31 December 2024. Investors must not rely on thi label with regard to investor protection issues and LuxFLAG does not incur any liability related to financial performance or default of the fund.			
MSCI	MSCI refers to the external data provider MSCI ESG Research LLC and/or its affiliates.			
MSCI ESG Methodology	For further information on the methodology applied to assess the ESG characteristics of the investments, please refer to www.msci.com/our-solutions/esg-investing.			
NAV	Net Asset Value			
Not ratable / No data coverage	Where MSCI considers an asset type for ESG analysis but data on an economic exposure is unavailable due to a lack of data from the data vendor, the investment falls under the category "No data coverage". Where MSCI considers an asset type out of scope for ESG analysis (e.g. Cash, Currency), the economic exposure falls under the category "Not ratable". For further information regarding excluded asset types, please refer to www.msci.com/our-solutions/esg-investing.			
Ongoing Charges	The calculation of the ongoing charge is based on the Committee of European Securities Regulators/10-674 Directive. For a maximum of 12 months from fund fisca year end and since inception, the ongoing charges figure is based on estimated expenses. After that, the ongoing charges correspond to the TER of the last annual report. It excludes performance fees and portfolio transaction costs, except in the case of an entry/exit charge paid by the fund when buying or selling shares/units in another collective investment undertaking.			
Portfolio ESG Rating	Discrepancies may exist between the portfolio-level ESG Rating calculated by CSAM applying the MSCI methodology (provided in this factsheet) and the ESG Rating displayed by other providers (e.g., MSCI ESG fund ratings). There are three main reasons for these potential deviations: (1) CSAM uses updated month-end holdings data as basis for its calculation, (2) CSAM consistently uses underlying issuer data where applicable (e.g., equity issuer in case of a convertible bond), and (3) look-through approach for target funds applied by CSAM. The coverage rate is security weighted. For further information on the MSCI methodology, please refer to www.msci.com/oursolutions/esg-investing/.			
QTD	Quarter-to-date			
Sustainable Finance Disclosure Regulation (SFDR)	Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector			
Sustainable investment	Where the 'sustainable investment objective' box is ticked, this means that the product implements CSAM investment strategies that allocate capital into companies that offer solutions to society's challenges and meet a sustainable investment objective. The sustainable investment objective is achieved through a dedicated investment process focusing on investments in themes and sectors whose economic activities address specific ESG challenges. An unticked box reflects that the product does not aim to meet a sustainable investment objective.			
objective				
objective Sustainable thematic	This product undertakes investments that are dedicated to addressing the United Nations Sustainable Development Goals (e.g. education or clean energy) through a thematic approach.			

Warning statements

Asset breakdown	Indicative allocation may change over time. All holdings are shown strictly for information purposes only and do not constitute investment recommendations of Credit Suisse. Please note that this does not constitute an offer or a solicitation to buy or sell any interest or any investment.
Swinging Single Pricing	For more details, please refer to the relevant chapter "Net Asset Value" of the fund's prospectus
Performance start date	Performance calculation and presentation start with the first full month of an invested strategy. This can lead to a difference in launch and performance start dates.
PRIIP SRI	The Summary Risk Indicator is a guide to the level of risk of this Product compared to other products. It shows how likely it is that the Product will lose money because of movements in the markets.

ESG Notes

The figures contained in this section are not audited. Where ESG related information, statements and scorings are made in this document, CS may have, partially or entirely, relied on publicly available information, internally developed data and/or information obtained from other third-party sources which CS believes to be reliable. CS' ability to verify such ESG objectives may be limited by the reliability of the data available in respect of the underlying assets and the status of the regulations in relation to tracking and providing such data. CS has not independently verified any information obtained from these public and third-party sources and cannot make any representations or warranties as to its accuracy, completeness or reliability. It is possible that the data from ESG data providers may be incorrect, unavailable, or not fully updated. This is especially true where CS has limited access to data from external parties regarding the underlying elements of an investment, for example due to a lack of look-through data. Such data gaps could result in an incorrect assessment of a sustainability practice and/or related sustainability risks and opportunities. Investors shall not use the ESG data provided in this document for the sake of meeting their own regulatory disclosure or reporting requirements. CS cannot make any guarantee about the content or completeness of such ESG disclosures, which remain subject to change and cannot be relied upon. In particular, CS shall not be liable for any errors or omissions in connection with any ESG data herein, or for any direct, indirect, special, punitive, consequential or any other damages (including lost profits). In the absence of a standardized, industry-wide ESG classification system, CS has developed its own ESG framework (the "CS Sustainable Investment Framework"). Therefore, investors should note that the ESG classification of the fund reflects CS' opinion and is based on the CS Sustainable Investment Framework which classification may vary from the classificatio

Want to learn more? Visit: https://credit-suisse.com/fundsearch

Important information

Source: Credit Suisse, unless otherwise specified

MSCI information was used herein; ©2024 MSCI and/or its affiliates. Used with permission all rights reserved; see msci.com/disclaimer.

This material constitutes marketing material of Credit Suisse AG and/or its affiliates (hereafter "CS").

This material does not constitute or form part of an offer or invitation to issue or sell, or of a solicitation of an offer to subscribe or buy, any securities or other financial instruments, or enter into any other financial transaction, nor does it constitute an inducement or incitement to participate in any product, offering or investment.

This marketing material is not a contractually binding document or an information document required by any legislative provision.

Nothing in this material constitutes investment research or investment advice and may not be relied upon. It is not tailored to your individual circumstances, or otherwise constitutes a personal recommendation, and is not sufficient to take an investment decision.

The information and views expressed herein are those of CS at the time of writing and are subject to change at any time without notice. They are derived from sources believed to be reliable. CS provides no guarantee with regard to the content and completeness of the information and where legally possible does not accept any liability for losses that might arise from making use of the

information. If nothing is indicated to the contrary, all figures are unaudited. The information provided herein is for the exclusive use of the recipient. The information provided in this material may change after the date of this material without notice and CS has no obligation to update the information

This material may contain information that is licensed and/or protected under intellectual property rights of the licensors and property right holders. Nothing in this material shall be construed to impose any liability on the licensors or property right holders. Unauthorised copying of the information of the licensors or property right holders is strictly prohibited. The full offering documentation including, the prospectus or offering memorandum, the Key Investor Information Document (KID), the Key Information Document (KID), the fund rules, as well as

The full offering documentation including, the prospectus or offering memorandum, the Key Investor Information Document (KID), the Key Information Document (KID), the fund rules, as well as the annual and bi-annual reports ("Full offering documentation"), as the case may be, may be obtained free of charge in one of the languages listed below from the legal entity/entities indicated below and where available via FundSearch (credit-suisse.com/fundsearch).

Information on your local distributors, representatives, information agent, paying agent, if any, and your local contacts in respect of the investment product(s) can be found below.

The only legally binding terms of any investment product described in this material, including risk considerations, objectives, charges and expenses are set forth in the prospectus, offering memorandum, subscription documents, fund contract and/or any other fund governing documents.

For a full description of the features of the products mentioned in this material as well as a full description of the opportunities, risks, and costs associated with the respective products, please refer to the relevant underlying securities prospectuses, sales prospectuses, or other additional product documents, which we will be pleased to provide to you at any time upon request.

The investment promoted in this marketing material concerns the acquisition of units or shares in a fund and not of any underlying assets. The underlying assets are owned by the fund only.

This material may not be forwarded or distributed to any other person and may not be reproduced. Any forwarding, distribution or reproduction is unauthorized and may result in a violation of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities referred to herein have not been, and will not be, registered under the Securities Act, or the securities laws of any states of the United States and, subject to certain exceptions, the securities may not be offered, pledged, sold or otherwise transferred within the United States or to, or for the benefit or account of, U.S. persons.

In addition, there may be conflicts of interest with regard to the investment.

In connection with the provision of services, Credit Šuisse AG and/or its affiliates may pay third parties or receive from third parties, as part of their fee or otherwise, a one-time or recurring fee (e.g., issuing commissions, placement commissions or trailer fees).

Prospective investors should independently and carefully assess (with their tax, legal and financial advisers) the specific risks described in available materials, and applicable legal, regulatory, credit, tax and accounting consequences prior to making any investment decision.

The alternative investment fund manager or the (UCITS) management company, as applicable, may decide to terminate local arrangements for the marketing of the shares/units of a fund, including terminating registrations or notifications with the local supervisory authority.

A summary of investor rights for investing into European Economic Area domiciled investment funds managed or sponsored by Credit Suisse Asset Management can be obtained in English via www.credit-suisse.com/am/regulatory-information, local laws relating to investor rights may apply.

Spain

Regulator / Supervisor legal entity: Comisión Nacional del Mercado de Valores ("CNMV"), Edison, 4, 28006 Madrid Spain, Tel: 34 91 585 15 00, Website: www.cnmv.es Distributor - if this material is distributed by: Credit Suisse AG, Sucursal en España*, Calle Ayala 42, 28001 Madrid, España

* Legal entity, from which the full offering documentation, the key investor information document (KIID), the fund rules, as well as the annual and bi-annual reports, if any, may be obtained free of charge.

Language versions available: English, German, French or Italian

Copyright © 2024 CREDIT SUISSE. All rights reserved.